Literature DB >> 11216673

Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines.

J Parmar1, E S Marshall, G A Charters, K M Holdaway, A N Shelling, B C Baguley.   

Abstract

Cell cultures exposed to DNA-damaging agents such as gamma radiation respond by arresting at cell cycle checkpoints, and the p53 tumor suppressor protein is strongly implicated in this behavior. We have investigated the TP53 status and cell cycle response to ionizing radiation of a series of early passage cell lines (designated NZM1 to NZM15) previously developed from patients with metastatic melanoma. The TP53 status of each of the cell lines was determined by single-strand conformation polymorphism and DNA sequence analysis. The majority of the lines appeared to have a wild-type TP53 gene sequence, consistent with published studies. Two lines (NZM4 and NZM7.2) were found to have an identical T-->C transition mutation in nucleotide 721 (exon 7) of the coding region. NZM7.2 (mutant) and NZM7.4 (wild-type) were clonally derived from the same line (NZM7). The existence of radiation-induced cell cycle arrest in G and/or G2M phase was determined 16 h after irradiation (6.3 Gy) by DNA staining and flow cytometric analysis. The mitotic inhibitor paclitaxel was used as a reference compound, with or without irradiation, to assess the efficiency of radiation-induced cell cycle arrest. G1 phase arrest was associated only with the presence of the wild-type TP53 gene, but the efficiency of induced arrest varied among the cell lines and the period of G phase arrest appeared to be short. A significant difference (P < 0.002) was also found between the efficiency of induction of G2 phase arrest and the presence of wild-type TP53 gene. The results provide evidence that although the melanoma cell lines generally had an intact TP53 gene, the efficiency of p53-mediated cycle arrest might be deficient and contribute to the resistance of this tumor to treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11216673     DOI: 10.3727/096504001108747620

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  10 in total

1.  Analysis of radiation-induced changes to human melanoma cultures using a mathematical model.

Authors:  B Basse; W R Joseph; E S Marshall; B C Baguley
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

2.  Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.

Authors:  Catherine J Drummond; Graeme J Finlay; Laura Broome; Elaine S Marshall; Emma Richardson; Bruce C Baguley
Journal:  Invest New Drugs       Date:  2010-06-22       Impact factor: 3.850

3.  The radiation protection and therapy effects of mesenchymal stem cells in mice with acute radiation injury.

Authors:  K X Hu; Q Y Sun; M Guo; H S Ai
Journal:  Br J Radiol       Date:  2010-01       Impact factor: 3.039

4.  Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel.

Authors:  Britta Basse; Bruce C Baguley; Elaine S Marshall; Wayne R Joseph; Bruce van Brunt; Graeme Wake; David J N Wall
Journal:  J Math Biol       Date:  2004-02-06       Impact factor: 2.259

5.  Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.

Authors:  Hamish S Sutherland; In Young Hwang; Elaine S Marshall; Brent S Lindsay; William A Denny; Catherine Gilchrist; Wayne R Joseph; Debra Greenhalgh; Emma Richardson; Philip Kestell; Angela Ding; Bruce C Baguley
Journal:  Invest New Drugs       Date:  2011-09-13       Impact factor: 3.850

6.  A mathematical model for analysis of the cell cycle in cell lines derived from human tumors.

Authors:  Britta Basse; Bruce C Baguley; Elaine S Marshall; Wayne R Joseph; Bruce van Brunt; Graeme Wake; David J N Wall
Journal:  J Math Biol       Date:  2003-05-15       Impact factor: 2.259

7.  Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.

Authors:  Ji Eun Kim; Clare Stones; Wayne R Joseph; Euphemia Leung; Graeme J Finlay; Andrew N Shelling; Wayne A Phillips; Peter R Shepherd; Bruce C Baguley
Journal:  BMC Cancer       Date:  2012-04-04       Impact factor: 4.430

8.  Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Authors:  Liangli Zhao; Elaine S Marshall; Lloyd R Kelland; Bruce C Baguley
Journal:  Invest New Drugs       Date:  2007-01-03       Impact factor: 3.651

9.  Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells.

Authors:  Marijke C C Sachweh; William C Stafford; Catherine J Drummond; Anna R McCarthy; Maureen Higgins; Johanna Campbell; Bertha Brodin; Elias S J Arnér; Sonia Laín
Journal:  Oncotarget       Date:  2015-06-30

10.  Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines.

Authors:  Ji Eun Kim; Euphemia Leung; Bruce C Baguley; Graeme J Finlay
Journal:  Front Genet       Date:  2013-05-31       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.